AVITA Medical (RCEL) Q2 2026 Earnings Call Transcript
AVITA Medical (RCEL) reported Q2 2026 revenue of $21.7M, up 18% year over year and 13% sequentially. RECELL revenue was $18.5M, Cohealyx $1.7M, and PermeaDerm $0.6M. Gross margin was 81.9%. Net loss was $7.7M ($0.25/share). Full-year 2026 guidance is $86M to $89M; cash flow breakeven targeted for Q4 2026.
How this was made
The 30-second read
Why it matters
Traders can update models around 2026 revenue growth, gross margin trajectory, and cash burn, with a key milestone of cash-flow breakeven targeted for Q4 2026.
Market read
Raised full-year 2026 revenue guidance, improved gross margin, reduced operating expenses, and provided a cash-flow breakeven timing target.
What to watch
The guidance range is broad ($86M-$89M) and depends on reimbursement stabilization and adoption; any delay in Medicare/CPT transition or clinical publication timing could pressure sentiment.
Background
AVITA Medical’s Q2 2026 earnings call focuses on RECELL scaling, expansion of the product portfolio (Cohealyx, PermeaDerm), and reimbursement/CPT-code developments affecting adoption.
Ticker impact
AVITA Medical reported Q2 revenue of $21.7M, raised 2026 guidance to $86M-$89M, and targeted cash-flow breakeven in Q4 2026.
Likely positive bias for the stock on earnings-day positioning, with follow-through dependent on whether RECELL growth and cash burn continue.
The article provides multiple decision-relevant datapoints: full-year revenue guidance range, gross margin expansion, operating expense reduction, and a stated breakeven timing milestone.
Market effects
Supports the acute wound care and regenerative medicine theme by signaling scaling of RECELL and improving unit economics (gross margin up).
Highlights international RECELL momentum (26% sequential RECELL revenue growth) and UK clinical experience, which may influence regional adoption expectations.
CMS reimbursement-related commentary and proposed CPT code changes could affect broader reimbursement dynamics for similar wound-care technologies.
Counterpoint
Despite revenue growth, the company still reports a sizable net loss ($7.7M) and low cash balance ($11.1M), so execution risk remains until breakeven.
Key entities
- companyAVITA Medical, Inc.
Subject of the earnings call transcript; reported Q2 results, updated 2026 guidance, and discussed reimbursement and product adoption.
- productRECELL
Autologous cell harvesting device; drove most revenue and margin expansion in Q2.
- productCohealyx
Collagen-based dermal matrix; management discussed clinical follow-up data timing and review activity.
- productPermeaDerm
Biosynthetic wound matrix; reported strong sequential growth in Q2.
- regulatorCMS
Proposed nationally published physician RVUs for skin cell suspension autograft codes, supporting reimbursement transparency.
